CD19 CAR T cells

BIOLOGICAL4 trials

Conditions

Acute Lymphoblastic Leukaemia RecurrentAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, B-precursorB-Cell Acute Lymphoblastic Leukemia, AdultLymphomas Non-Hodgkin's B-CellNon-Hodgkin Lymphoma, B-cellRelapse

Early Phase 1

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

Not yet recruitingNCT07277504

The General Hospital of Western Theater CommandB-Cell Acute Lymphoblastic Leukemia, Adult

Start: 2025-12-01End: 2031-12-31Target: 50Updated: 2025-12-11

Phase 1

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

NCT02772198

Sheba Medical CenterAcute Lymphoblastic Leukemia, B-precursor, Non-Hodgkin Lymphoma, B-cell

Start: 2016-11-30End: 2022-11-30Target: 300Updated: 2020-11-03

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

CompletedNCT02975687

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukaemia Recurrent, Acute Lymphoblastic Leukemia, Adult B-Cell

Start: 2016-11-30End: 2018-12-31Updated: 2025-06-03

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

CompletedNCT03029338

Institute of Hematology & Blood Diseases Hospital, ChinaLymphomas Non-Hodgkin's B-Cell, Relapse

Start: 2017-06-08End: 2021-06-22Updated: 2026-02-11

Blood2025-11-03

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma

Chinese Medical Journal2025-09-17

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood2024-11-051 citations

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Journal for ImmunoTherapy of Cancer2024-04-0125 citations

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Blood2023-11-02

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION

HemaSphere2023-08-011 citations

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Blood2022-11-151 citations

P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

HemaSphere2022-06-01

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Blood2020-11-0544 citations

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Journal of Hematology & Oncology2020-09-07107 citations

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients

Journal for ImmunoTherapy of Cancer2020-03-0149 citations

Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.

2019-12-2519 citations

Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies

Blood2019-11-1318 citations

The Efficacy and Safety of Anti-CD19 CAR T-Cell Therapy in Young Adults with Relapsed and Refractory Aggressive B-Cell Malignancies—the Experience of a Single Center in Israel

Blood2017-12-07

CD19 CAR T cells

Sponsors

Conditions

Early Phase 1

Phase 1

Related Papers